Results 31 to 40 of about 121,016 (287)

Engineering and Design of Chimeric Antigen Receptors

Molecular Therapy: Methods & Clinical Development, 2019
T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers.
Sonia Guedan, Hugo Calderon, Avery D. Posey, Jr., Marcela V. Maus   +3 more
doaj   +1 more source

Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives [PDF]

, 2003
While modern treatments have led to a dramatic improvement in survival for pediatric malignancy, toxicities are high and a significant proportion of patients remain resistant.
Biagi, Ettore, Bollard, Catherine, Brenner, Malcolm, Rousseau, Raphael   +3 more
core   +5 more sources

Chimeric antigen receptor T cell

Indian Journal of Pharmacology, 2022
During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2/neu inhibitor, has been developed and accepted widely for management of chronic myeloid leukaemia and breast cancer ...
Singh, Surjit, Khasbage, Sameer, Kaur, Rimple Jeet, Sidhu, Jaspreet Kaur, Bhandari, Bharti   +4 more
openaire   +2 more sources

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]

, 2012
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
A Lundqvist, A Somers, C Berger, CA Tran, Carolina Berger, Cornelis JM Melief, Daniel J Powell, David F Stroncek, DG Song, DJ Powell Jr, DL Porter, Francesco M Marincola, G Mostoslavsky, GG Kenter, Gustavo Mostoslavsky, J Jin, J Staerk, James R Heath, Jeffrey S Miller, JN Kochenderfer, JN Kochenderfer, John O'Shea, JS Miller, K Takahashi, L Gattinoni, L Gattinoni, L Gattinoni, L Gattinoni, LA Johnson, Luca Gattinoni, M Kalos, M Kalos, M Kalos, Mahendra Rao, Mark E Dudley, Martin A Cheever, ME Dudley, ME Dudley, Michael Kalos, Nicholas P Restifo, P Muranski, Peter Flynn, PF Robbins, RA Morgan, Richard W Childs, SA Rosenberg, Steven A Rosenberg, TS Park, X Wang   +48 more
core   +4 more sources

Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation

Haematologica, 2020
Allogeneic hematopoietic stem cell transplantation is an effective therapy for high-risk leukemias. In children, graft manipulation based on the selective removal of αβ T cells and B cells has been shown to reduce the risk of acute and chronic graft ...
Volker Wiebking, Ciaran M. Lee, Nathalie Mostrel, Premanjali Lahiri, Rasmus Bak, Gang Bao, Maria Grazia Roncarolo, Alice Bertaina, Matthew H. Porteus   +8 more
doaj   +1 more source

Circumventing antivector immunity: potential use of nonhuman adenoviral vectors [PDF]

, 2014
Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase
Beard C.W., Benkö M., Cauthen A.N., Crawford-Miksza L., Estrella Lopez-Gordo, Gall J., Gall J.G., Gattoni A., Ginsberg H.S., Haviv Y.S., Hofmann C., Iva I. Podgorski, Kajon A.E., Kanerva A., Kass-Eisler A., Kuriyama S., Mastrangeli A., Michou A.I., Nicholas Downes, Ramon Alemany, Rogozhin V.N., Roy S., Seiradake E., Shmarov M.M., Soudais C., Tutykhina I.L., Wang D.Y., Wohlfart C., Ying B., Zakhartchouk A.N., Zeng Q.   +30 more
core   +3 more sources

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

Nature Communications, 2020
Chimeric antigen receptors (CAR) use antibody variable regions to activate anti-tumor immunity. Here the authors show that a mouse IgH/IgL variable region used in a clinical CAR induces host immune responses to possibly reduce therapy efficacy, but an ...
Norris Lam, Nathan D. Trinklein, Benjamin Buelow, George H. Patterson, Namrata Ojha, James N. Kochenderfer   +5 more
doaj   +1 more source

CAR-T Cells: Precision Cancer Immunotherapy

Indonesian Biomedical Journal, 2018
BACKGROUND: Current cancer drugs and treatments are aiming at eradicating tumor cells, but often are more toxic then effective, killing also the normal cells and not selectively the tumor cells.
Anna Meiliana, Nurrani Mustika Dewi, Andi Wijaya   +2 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy.

Australian prescriber, 2023
Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achieving prolonged remission.
Burge, Cale, Vanguru, Vinay, Ho, Phoebe Joy   +2 more
openaire   +2 more sources

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.

PLoS ONE, 2015
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although mainly second generation (2G) CARs carrying CD28 or 4-1BB have been investigated in patients, preclinical studies suggest that third generation (3G) CARs
Hannah Karlsson, Emma Svensson, Camilla Gigg, Malin Jarvius, Ulla Olsson-Strömberg, Barbara Savoldo, Gianpietro Dotti, Angelica Loskog   +7 more
doaj   +1 more source